Overview

A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder

Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
This is a Phase IIa study to evaluate the efficacy, safety and tolerability of GW679769 vs placebo on symptoms of urgency with urge incontinence, frequency and nocturia associated with overactive bladder in women.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Casopitant